SELLAS Life Sciences Group, Inc. SLS

Retail investors speculated that Sellas’ office lease through September 2027 provides stability for clinical results and potential deal discussions.

Shares of Sellas Life Sciences Group Inc. (NASDAQ:SLS) nosedived by 16.6 percent in the third quarter of the year—from $14.76 on June 30 to $12.31 on Wednesday—as sentiment was dragged down by the delays and uncertainties surrounding the clinical results of its treatment candidate for acute myeloid leukemia (AML). In Wednesday’s trading alone, the stock […]

SELLAS Life Sciences Group, Inc. recently reported preclinical data at an AACR pancreatic cancer conference showing its CDK9 inhibitor SLS009 induced meaningful cancer cell death in MYC-amplified, daraxonrasib-resistant pancreatic ductal adenocarcinoma organoid models, both alone and in combinations. The findings highlight SLS009’s potential to address RAS inhibitor resistance and show synergistic effects when paired with BET inhibitor ZEN3694 at relatively low exposure levels. We’ll now...

SELLAS Life Sciences Group has delivered a very large 3 year return, which puts a spotlight on whether the current share price around US$11.51 still lines up with what its balance sheet is worth on paper. With that kind of move behind it and new cancer therapy data in play, the question now is how much value investors are effectively placing on SELLAS' book value. Over the past 3 years, the stock has gained roughly 7x. This makes the relationship between its recent share price performance...

SELLAS Life Sciences Group (SLS) presented new preclinical data on September 25, 2026, highlighting its CDK9 inhibitor SLS009 in pancreatic cancer organoid models at an AACR pancreatic cancer conference. SELLAS Life Sciences Group shares trade at US$11.51 after a 1-day share price return that declined 0.69%, extending a 30-day share price drop of 12.87%. Yet the 1-year total shareholder return is very large at more than 6x and the 3-year total shareholder return is also very large, hinting...

IOVA surged 77% and IBRX gained 11%, bucking biotech’s decline, while SLS fell 14% and VNDA slipped 7%.

SLS investors have been closely watching for two key developments: late-stage REGAL study data for the company’s GPS cancer vaccine in acute myeloid leukemia and a decision on whether SLS009 will advance into human trials for pancreatic cancer.

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009

Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

DelveInsight's Cancer Vaccines Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Melanoma, Lung Cancer (NSCLC), Bladder Cancer, Prostate Cancer, Breast Cancer, Pancreatic Cancer, Head and Neck Cancer, Cervical Cancer, and Other Solid Tumors. The selected indications are based on approved therapies and ongoing pipeline activity.

Novo Nordisk (NVO) will hold its 2026 Capital Markets Day in London on Monday.

The rally followed a Nant Capital-led financing worth up to $22.3 million, with $11.3 million raised at the initial close.

J&J’s recent deals include the $3.05 billion Halda acquisition and $1 billion Firefly purchase, while Pfizer’s Innovent deal is worth up to $10.5 billion.

ImmunityBio is attending major conferences in Seoul and New York, followed by several oncology events through November.

Its IBRX stake jumped 27.5% to 243,678 shares worth $2.13 million, bringing both positions’ combined value to $2.86 million.

SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

Three abstracts evaluating SLS009 have been accepted for poster presentations at the AACR Conference on Pancreatic Cancer later in September.

- Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

Sellas is gaining Wall Street’s attention as clinical progress, upcoming catalysts, and positive analyst sentiment strengthen the case for further upside.

Retail traders viewed the Merida acquisition as evidence that Big Pharma will pay rich premiums for immune-focused platforms.